JP2015519313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519313A5 JP2015519313A5 JP2015507425A JP2015507425A JP2015519313A5 JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5 JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- amino acid
- fviii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12165296 | 2012-04-24 | ||
| EP12165296.0 | 2012-04-24 | ||
| US201261641439P | 2012-05-02 | 2012-05-02 | |
| US61/641,439 | 2012-05-02 | ||
| EP13150575 | 2013-01-09 | ||
| EP13150575.2 | 2013-01-09 | ||
| US201361752614P | 2013-01-15 | 2013-01-15 | |
| US61/752,614 | 2013-01-15 | ||
| PCT/EP2013/055107 WO2013160005A1 (en) | 2012-04-24 | 2013-03-13 | Pharmaceutical composition suitable for treatment of haemophilia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015519313A JP2015519313A (ja) | 2015-07-09 |
| JP2015519313A5 true JP2015519313A5 (enExample) | 2016-04-14 |
Family
ID=49482214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507425A Withdrawn JP2015519313A (ja) | 2012-04-24 | 2013-03-13 | 血友病の治療に適する医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20150045303A1 (enExample) |
| EP (1) | EP2841091A1 (enExample) |
| JP (1) | JP2015519313A (enExample) |
| CN (1) | CN104411323A (enExample) |
| WO (1) | WO2013160005A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102741275B (zh) | 2009-08-24 | 2016-08-03 | 阿穆尼克斯运营公司 | 凝血因子ix组合物及其制备和使用方法 |
| LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| AR101060A1 (es) * | 2014-02-12 | 2016-11-23 | Novo Nordisk As | Conjugados de fviii |
| CA2949323A1 (en) | 2014-06-06 | 2015-12-10 | Octapharma Ag | Preparation comprising factor viii and von willebrand factor peptides |
| WO2016198521A1 (en) | 2015-06-10 | 2016-12-15 | Novo Nordisk A/S | Fviii fusion proteins |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| EP3205665A1 (en) * | 2016-02-11 | 2017-08-16 | Octapharma AG | Method of separating factor viii from blood products |
| TW201828974A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Ｃｓｌ貝林重組技能公司 | 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| US11141466B2 (en) | 2017-06-22 | 2021-10-12 | CSL Behring Lengnau AG | Modulation of FVIII immunogenicity by truncated VWF |
| CN108753910A (zh) * | 2018-05-16 | 2018-11-06 | 浙江思格医疗科技有限公司 | 一种消化液 |
| CN108918235A (zh) * | 2018-05-16 | 2018-11-30 | 绍兴文理学院 | 一种肿瘤淋巴结离体标本的固定处理方法 |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| EP3870206A4 (en) * | 2018-10-23 | 2023-04-26 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION |
| KR20220029733A (ko) * | 2019-07-04 | 2022-03-08 | 체에스엘 베링 렝나우 아게 | 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf) |
| WO2021032646A1 (en) | 2019-08-16 | 2021-02-25 | Octapharma Ag | Stabilizing buffer for factor viii and vwf |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952198A (en) * | 1995-05-04 | 1999-09-14 | Bayer Corporation | Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition |
| EP2042196B1 (en) | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| CA2656558A1 (en) * | 2006-06-30 | 2008-01-10 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| AU2008261261B2 (en) * | 2007-06-13 | 2013-06-27 | Csl Behring Gmbh | Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders |
| DK2257311T3 (da) | 2008-02-27 | 2014-06-30 | Novo Nordisk As | Konjugerede Faktor VIII-Molekyler |
| KR20110093775A (ko) | 2008-11-03 | 2011-08-18 | 바이엘 헬스케어 엘엘씨 | 혈우병 치료 방법 |
| GB0911870D0 (en) * | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| US9493543B2 (en) | 2010-02-16 | 2016-11-15 | Novo Nordisk A/S | Factor VIII fusion protein |
| US20130183280A1 (en) * | 2010-07-15 | 2013-07-18 | Novo Nordisk A/S | Stabilized factor viii variants |
| JP6042335B2 (ja) | 2010-09-15 | 2016-12-14 | ノヴォ ノルディスク アー／エス | 細胞取込みが低下した第ｖｉｉｉ因子変異体 |
-
2013
- 2013-03-13 WO PCT/EP2013/055107 patent/WO2013160005A1/en not_active Ceased
- 2013-03-13 EP EP13713368.2A patent/EP2841091A1/en not_active Withdrawn
- 2013-03-13 CN CN201380033402.5A patent/CN104411323A/zh not_active Withdrawn
- 2013-03-13 US US14/396,833 patent/US20150045303A1/en not_active Abandoned
- 2013-03-13 JP JP2015507425A patent/JP2015519313A/ja not_active Withdrawn
-
2015
- 2015-11-06 US US14/934,196 patent/US20160120954A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081042A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g | |
| BR112021022315A2 (pt) | Ligantes de peptídeo bicíclicos específicos para ox40 | |
| NO20092774L (no) | HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette | |
| JP2018522563A5 (enExample) | ||
| JP2012522529A5 (enExample) | ||
| CY1115841T1 (el) | Εμβολια πεπτιδιου παραγομενα απο epha4 | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
| CN101687022A8 (zh) | Prame衍生的肽以及包括该肽的免疫原组合物 | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| WO2013036778A3 (en) | Compstatin analogs with improved pharmacokinetic properties | |
| JP2012532601A5 (enExample) | ||
| RU2015146614A (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
| UA103882C2 (uk) | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина | |
| WO2012112690A3 (en) | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains | |
| HRP20161305T1 (hr) | Liječenje mikrobnih infekcija | |
| WO2012006598A3 (en) | Stabilized insulinotropic peptides and methods of use | |
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| JP2013532176A5 (enExample) | ||
| MX2025012580A (es) | Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal | |
| BR112018003580A2 (pt) | molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante | |
| JP2018526987A5 (enExample) | ||
| WO2015054439A3 (en) | Hybrid factor viii polypeptides for use to treat hemophilia a | |
| EP3556857A3 (en) | Cdc45l peptides and vaccines including the same |